The 14 most recent market catalysts affecting $UCB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 55
UCB and Biogen Present New Clinical Data for Dapirolizumab Pegol at ACR Convergence 2026
This 8-K filing discloses that UCB and Biogen are presenting additional clinical data for dapirolizumab pegol (DZP), an investigational treatment for systemic lupus erythematosus (…
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 65
UCB and Biogen Present New Clinical Data for Dapirolizumab Pegol in Lupus
UCB and Biogen jointly announced the presentation of new clinical data for dapirolizumab pegol (DZP), their investigational biologic for systemic lupus erythematosus (SLE), at the …
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 65
UCB Announces Positive Week 24 Data for BIMZELX (bimekizumab-bkzx) from BE BOLD Study
UCB released new data from its BE BOLD study for BIMZELX, showing that the drug maintained clinical improvements in patients through Week 24. This is significant because it confirm…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
UCB Selects Veeva Vault CRM for Global Customer Engagement
UCB, a biopharmaceutical company, has chosen Veeva Vault CRM to power its global customer engagement strategy. This decision signifies UCB's commitment to leveraging advanced techn…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
UCB Advances Digital Antibody Engineering Program with Cradle Collaboration
UCB, a global biopharmaceutical company, has partnered with Cradle, an AI-driven protein design company, to advance its digital antibody engineering program. This collaboration is …
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 65
AlphaValue/Baader Europe Raises Forecasts for UCB
AlphaValue/Baader Europe has raised its forecasts for UCB SA, directly in response to UCB's recent decision to increase its financial outlook for the 2026 fiscal year. This is sign…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 75
BofA Raises Price Target and EPS Forecasts for UCB Following FY26 Guidance Increase
UCB recently surprised analysts by increasing its fiscal year 2026 guidance, a move that has now prompted Bank of America to raise its price target and EPS forecasts for the compan…
Oct 23, 2026
Corporate Catalyst
Bearish
Impact 65
AlphaValue/Baader Europe Downgrades UCB to Sell
AlphaValue/Baader Europe has downgraded its rating for biopharmaceutical company UCB SA to 'Sell'. This analyst action indicates a revised, more pessimistic outlook on UCB's equity…
Oct 20, 2026
Corporate Catalyst
Bullish
Impact 65
United Community Banks Q3 Adj. EPS $0.77, Inline, Sales $291.905M Beat $282.540M Estimate
United Community Banks (UCB) announced its Q3 earnings, revealing adjusted EPS of $0.77, which was in line with analyst consensus. More notably, the company's sales of $291.905 mil…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 55
Keefe, Bruyette & Woods Maintains Outperform on United Community Banks, Raises Price Target to $41
Keefe, Bruyette & Woods analyst Will Jones maintained an 'Outperform' rating on United Community Banks (UCB) and raised the price target from $40 to $41. This action signals contin…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
DA Davidson Maintains Buy on United Community Banks, Raises Price Target to $42
DA Davidson analyst Gary Tenner has maintained a 'Buy' rating on United Community Banks (UCB) and raised the price target from $40 to $42. This action signals continued confidence …
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 65
United Community Appoints Tom Speir CFO, Effective Sept. 8, Succeeding Jefferson Harralson
United Community (UCB) is appointing Tom Speir as its new CFO, replacing Jefferson Harralson who is retiring. This is a significant leadership change for the company, as the CFO pl…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 85
Transcript: United Community Banks Q2 2026 Earnings Conference Call
United Community Banks (UCB) delivered a strong Q2 2026, with operating EPS up 8% and total revenue up 7% year-over-year. The net interest margin improved, and loan growth, particu…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 92
United Community Banks Q2 Adj. EPS $0.71 Misses $0.81 Estimate, Sales $279.280M Miss $280.077M Estimate
United Community Banks (UCB) announced its Q2 earnings, revealing a substantial miss on adjusted EPS, coming in at $0.71 against an $0.81 estimate, a 12.35% deviation. Sales also s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.